Biologic Graft Failure: Causes, Assessment, and Re-Intervention Protocol

A biologic allograft is applied to a prepared diabetic foot ulcer. The team follows the protocol: debridement to a viable base, hemostasis, moisture balance, proper fixation. Two weeks later, the graft has not integrated. The membrane is lifting at the margins, the wound bed beneath is pale, and granulation has stalled. The clinical question is immediate: has the graft failed, and if so, why?

Biologic graft failure is not a single event. It is the outcome of one or more unaddressed barriers — infection, inadequate wound-bed preparation, moisture imbalance, sizing errors, or patient comorbidities — that prevent the allograft from establishing the tissue contact it needs to deliver its regenerative signals. This protocol frames how to assess whether a graft has truly failed, identify the root cause, and structure a re-intervention decision that is clinically sound and payer-documentable.

Common Causes of Biologic Graft Failure

Graft failure rarely has a single cause. The following categories account for the majority of non-integration events in clinical practice.

Infection and biofilm burden. Biofilm is present in the majority of chronic wounds and can re-establish mature architecture within 24 to 72 hours after debridement (Wolcott et al., 2009). A graft on a surface with uncontrolled biofilm — or one that has recolonized between debridement and application — will fail to integrate because the inflammatory and proteolytic environment degrades both the graft and nascent granulation tissue. Spreading infection, cellulitis, or untreated osteomyelitis will cause failure regardless of graft quality (Schultz et al., 2017; Ivory et al., 2025).

Inadequate wound-bed preparation. The TIME framework defines readiness, and a graft placed when any domain is uncontrolled is at risk (Schultz et al., 2003; Harries et al., 2016). A wound bed with residual slough, fibrinous debris, or poor-quality granulation does not provide the vascularized surface required for graft integration.

Moisture imbalance. A graft on a dry bed desiccates and fails to adhere. A graft on a heavily exuding bed floats, macerates surrounding tissue, and lifts at the edges. Both extremes compromise the tissue contact that integration depends on.

Sizing and coverage errors. A graft that is too small leaves exposed wound surface vulnerable to desiccation and bacterial invasion. A graft that significantly overlaps intact periwound skin wastes material and may compromise edge adherence. Most amniotic membrane products are applied with 1 to 2 mm overlap onto intact periwound skin for edge fixation.

Patient comorbidities. Diabetes with poor glycemic control, peripheral arterial disease, malnutrition, smoking, immunosuppression, and poor adherence to offloading or compression all reduce the probability of graft integration. Ischemic beds do not support graft take regardless of preparation quality (Han & Ceilley, 2017). Vascular assessment — ABI, toe pressures, transcutaneous oxygen, or Doppler waveforms — should confirm adequate perfusion before any biologic application.

Assessing True Failure vs. Slow Integration

Not every graft that looks poor at one week has failed. Distinguishing true failure from slow integration requires assessment against clinical signs and timeframe expectations.

Signs of graft failure include: membrane lifting or separating from the wound bed; purulent or malodorous drainage beneath or around the graft; dark, necrotic discoloration; complete absence of granulation tissue beneath the graft; and frank dissolution of the graft material. These signs indicate that integration is not occurring.

Signs of slow but viable integration include: partial adherence with some edge lifting but central take; progressive but modest granulation beneath the graft; and absence of infection signs. Some amniotic membrane products integrate gradually over several weeks, and appearance at one week may not predict the final outcome.

Timeframe expectations. Clinical trials of amniotic membrane in diabetic foot ulcers assess healing at 6 to 12 weeks, with applications repeated weekly or biweekly (Lavery et al., 2014; DiDomenico et al., 2018; Zelen et al., 2016). A single application that has not produced measurable wound area reduction by the next visit warrants assessment, but does not by itself constitute therapeutic failure. The question is whether the wound is progressing across serial applications.

If the graft has truly failed — lifting, purulence, no granulation, active infection — proceed to root-cause assessment before re-application.

The Re-Intervention Decision Framework

This framework structures the re-intervention decision. It is clinical decision support, not a treatment mandate. Individual patient factors — vascular status, comorbidities, nutritional status, adherence capacity — modify every step.

Step 1: Identify and address the root cause. Before re-applying any biologic, determine why the first graft failed. If infection was the cause, treat it first — topical antimicrobials for localized biofilm, systemic antibiotics for spreading infection, surgical intervention for osteomyelitis. If moisture imbalance was the cause, adjust the dressing regimen. If perfusion was inadequate, obtain vascular consultation. Re-applying a biologic without addressing the underlying cause will reproduce the failure.

Step 2: Re-debride to a viable base. Regardless of root cause, the wound bed must be returned to a viable, granular, bleeding state before any re-application. Remove residual non-viable graft material, slough, and biofilm. Document the debridement method, depth, and resulting wound characteristics (Wolcott et al., 2009; Schultz et al., 2017).

Step 3: Confirm all TIME readiness criteria are met. Before re-application, the wound must satisfy each domain: viable tissue bed, controlled infection, balanced moisture, and accessible wound edges. If any criterion is not met, delay re-application and return to preparation (Schultz et al., 2003; Harries et al., 2016).

Step 4: Decide whether to re-apply the same product type or switch. If the failure was caused by a correctable preparation or patient factor — and that factor is now resolved — re-applying the same biologic is reasonable. If the failure appears related to product-wound mismatch — for example, a heavily exuding wound where a dehydrated membrane could not maintain adherence — switching to a product with different handling characteristics may be appropriate. Product selection is guided by wound characteristics, handling requirements, and manufacturer Instructions for Use.

Step 5: Escalate to surgery when indicated. If repeated biologic applications fail despite optimal preparation, if the wound exposes tendon, bone, or joint capsule without coverage, or if vascular insufficiency cannot be corrected, surgical intervention — including flap coverage or revascularization — may be necessary. Biologic allografts are adjuncts to, not replacements for, surgical judgment.

Payer Documentation for Re-Application After Failure

Re-application after graft failure requires documentation that establishes medical necessity and distinguishes the new application from the failed one. Medicare Local Coverage Determinations (LCDs) for skin substitutes require specific elements in the clinical record:

• Wound measurements (length x width x depth) at each visit, with the trajectory showing continued non-healing despite the prior biologic application.
• Root-cause assessment documenting why the prior graft failed and what corrective action was taken.
• Re-debridement documentation — method, date, and resulting wound bed characteristics confirming readiness for re-application.
• Clinical rationale linking the wound's stalled trajectory, the corrected barrier, and the decision to re-apply.
• Product information — HCPCS code, application date, graft size, and number of units applied.

Common denial reasons include missing documentation of why the first graft failed, no evidence the root cause was corrected, and absent wound measurement trajectory. These are documentation failures, not clinical failures.

Clinical Judgment and Individual Factors

This protocol is a decision framework, not a universal standard. The evidence on biologic re-application after failure is limited — most clinical trials report outcomes from serial applications as a package, without isolating the re-intervention decision (Lavery et al., 2014; DiDomenico et al., 2018; Zelen et al., 2016). The decision to re-apply, switch products, or escalate to surgery depends on the wound's biology, the patient's overall condition, and institutional resources. Individual patient factors may vary, and no outcome guarantees are implied by this framework.

References

1. Schultz GS, Sibbald RG, Falanga V, et al. Wound bed preparation: a systematic approach to wound management. Wound Repair Regen. 2003;11(Suppl 1):S1-S28. PMID: 12654015.

2. Harries RL, Bosanquet DC, Harding KG. Wound bed preparation: TIME for an update. Int Wound J. 2016;13(Suppl 3):8-14. PMID: 27547958.

3. Wolcott RD, Kennedy JP, Dowd SE. Biofilm maturity studies indicate sharp debridement opens a time-dependent therapeutic window. J Wound Care. 2009;18(4):145-151. PMID: 20852503.

4. Schultz G, Bjarnsholt T, Dubertret T, et al. Consensus guidelines for the identification and treatment of biofilms in chronic nonhealing wounds. Wound Repair Regen. 2017;25(5):744-757.

5. Ivory JD, Sezgin D, Coutts PM, et al. Clinical signs and symptoms of biofilm in chronic wounds: what do practitioners think? Consensus through an electronic Delphi survey. Int Wound J. 2025;22(11):e70771. PMID: 41185925.

6. Han G, Ceilley R. Chronic wound healing: a review of current management and treatments. Adv Ther. 2017;34(3):599-610. PMID: 28108895.

7. Lavery LA, Fulmer J, Shebetka KA, et al. The efficacy and safety of Grafix for the treatment of chronic diabetic foot ulcers. Int Wound J. 2014;11(5):554-560. PMID: 25048468.

8. DiDomenico LA, Orgill DP, Galiano RD, et al. Use of an aseptically processed, dehydrated human amnion and chorion membrane improves likelihood and rate of healing in chronic diabetic foot ulcers. Int Wound J. 2018;15(6):950-957. PMID: 30019528.

9. Zelen CM, Gould L, Serena TE, et al. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers. Int Wound J. 2016;13(2):165-172. PMID: 25424146.

10. CMS. Local Coverage Determination (LCD) for Skin Substitute Grafts/Cellular and Tissue-Based Products for Chronic Wounds. Medicare Administrative Contractor coverage policy. Verify current LCD for your MAC jurisdiction.

11. Bus SA, Lavery LA, Monteiro-Soares M, et al. IWGDF Guideline on the prevention and management of diabetes-related foot disease. Diabetes Metab Res Rev. 2024;40(Suppl 3):e3654.

Related Resources

• Wound Bed Preparation Before Biologic Application: A Clinical Protocol
• Optimal Timing of Biologic Application After Debridement
• When to Escalate to Biologics in Non-Healing Wounds
• Chronic Wound Biofilm Management: Pre-Graft Debridement Protocol